Using cardiac biomarkers and treating cardiotoxicity in cancer

Future Cardiology

Volumn 9, Issue 1, 2013, Pages 105-118

  Colombo, Alessandro ^a   Cardinale, Daniela ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

blockers; ACEI; biomarkers; cancer therapy; cardiotoxicity; left ventricular dysfunction; natriuretic peptides; prevention; treatment; troponin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CLOFARABINE; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; IDARUBICIN; IFOSFAMIDE; IMATINIB; INTERLEUKIN 6; LAPATINIB; SUNITINIB; TRASTUZUMAB; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; APOPTOSIS; CANCER CHEMOTHERAPY; CARDIAC IMAGING; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ECHOCARDIOGRAPHY; COUGHING; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART REPOLARIZATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOKINETIC CARDIOMYOPATHY; MEDICAL HISTORY; MYOCARDITIS; OXIDATIVE STRESS; PATHOGENESIS; PERICARDITIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QT INTERVAL; REAL TIME ECHOGRAPHY; REVIEW; RISK REDUCTION; THREE DIMENSIONAL ECHOCARDIOGRAPHY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; NEOPLASMS; TROPONIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84871560746     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.73     Document Type: Review

References (105)

1. Herbst RS, Bajorin DF, Bleiberg H et al. American Society of Clinical Oncology. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J. Clin. Oncol. 24(1), 190-205 (2006).
2. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53(24), 2231-2247 (2009).
3. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev. Anticancer Ther. 6(9), 1249-1269 (2006).
4. Barry E, Alvarez JA, Scully RE et al. Anthracycline induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin. Pharmacother. 8(8), 1039-1058 (2007).
5. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin. Oncol. 25(4 Suppl. 10), S72-S85 (1998).
6. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention. Drug Saf. 22(4), 263-302 (2000).
7. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94(4), 525-533 (2008).
8. Youssef G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am. J. Cardiovasc. Drugs 5(4), 233-243 (2005).
9. Wouters KA, Kremer LC, Miller TL et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131(5), 561-578 (2005).
10. Steinherz LJ, Steinherz PG, Tan CTC et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266(12), 1672-1677 (1991).
11. Silber JH, Jakacki RI, Larsen RL et al. Increased risk of cardiac dysfunction after anthracyclines in girls. Med. Pediatr. Oncol. 21(7), 477-479 (1993).
12. Steinherz LJ. Anthracycline-induced cardiotoxicity. Ann. Intern. Med. 126(10), 827-828 (1997).
13. Silber JH, Cnaan A, Clark BJ et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. 22(5), 820-828 (2004).
14. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 31, 459-467 (2008).
15. Suter TM, Ewer MS. Trastuzumab-associated cardiotoxicity. In: Cancer and the Heart. Ewer MS, Yeh ETH (Eds). BC Decker Inc., Hamilton, ON, Canada 64-67 (2006).
16. Jones AL, Barlow M, Barrett-Lee PJ et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br. J. Cancer 100(5), 684-692 (2009).
17. Rastogi P, Jeong J, Geyer CE et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)3paclitaxel (T) vs. AC3T with trastuzumab (H). J. Clin. Oncol. 25, 6S (2007) (Abstract LBA513).
18. Bovelli D, Plataniotis G, Roila F. ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann. Oncol. 21(Suppl. 5), v277-v282 (2010).
19. Eschenhagen T, Force T, Ewer MS et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 13(1), 1-10 (2011).
20. Schwartz RG, McKenzie WB, Alexander J et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am. J. Med. 82(6), 1109-1118 (1987).
21. Mitani I, Jain D, Joska TM et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J. Nucl. Cardiol. 10(2), 132-139 (2003).
22. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin. Cancer Res. 14(1), 14-24 (2008).
23. Nielsen D, Jensen JB, Dombernowsky P et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J. Clin. Oncol. 8(11), 1806-1810 (1990).
24. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann. Oncol. 13(5), 699-709 (2002).
25. Galderisi M, Marra F, Esposito R et al. Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc. Ultrasound 5, 4 (2007).
26. Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr. Hypertens. Rep. 12(6), 404-410 (2010).
27. Braunwald E. Biomarkers in heart failure. N. Engl. J. Med. 358(20), 2148-2159 (2008).
28. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology for the redefinition of myocardial infarction. Eur. Heart J. 21(18), 1502-1513 (2000).
29. O'Brien PJ. Cardiac troponin is the most effective translational safetybiomarker for myocardial injury in cardiotoxicity. Toxicology 245(3), 206-218 (2008).
30. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur. Heart J. 25(14), 1187-1196 (2004).
31. Jensen JK, Atar D, Mickley H. Mechanism of troponin elevations in patients with acute ischemic stroke. Am. J. Cardiol. 99(6), 867-870 (2007).
32. Adamcova M, Sterba M, Simunek T et al. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin. Drug Saf. 4(3), 457-472 (2005).
33. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf. 25(5), 301-311 (2002).
34. Herman EH, Lipshultz SE, Rifai N et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 58(2), 195-197 (1998).
35. Urbanova D, Urban L, Carter A et al. Cardiac troponins-biochemical markers of cardiac toxicity after cytostatic therapy. Neoplasma 53(3), 183-190 (2006).
36. Lipshultz SE, Rifai N, Sallan SE et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96(8), 2641-2648 (1997).
37. Lipshultz SE, Rifai N, Dalton VM et al. The effects of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med. 351(2), 145-152 (2004).
38. Lipshultz SE, Scully RE, Lipsitz SR et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 11(10), 950-961 (2010).
39. Lipshultz SE, Miller TL, Scully RE et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term chocardiographic outcomes. J. Clin. Oncol. 30(10), 1042-1049 (2012).
40. Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll. Cardiol. 36(2), 517-522 (2000).
41. Zaninotto M, Altinier S, Lachin M et al. Fluoroenzymometric method to measure cardiac troponin I in sera of patients with myocardial infarction. Clin Chem. 42(9), 1460-1466 (1996).
42. Morandi P, Ruffini PA, Benvenuto GM et al. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m2) cyclophosphamide. Bone Marrow Transplant. 28(3), 277-282 (2001).
43. Cardinale D, Sandri MT, Martinoni A et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann. Oncol. 13(5), 710-715 (2002).
44. Auner HW, Tinchon C, Brezinschek RI et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur. J. Haematol. 69(1), 1-6 (2002).
45. Sandri MT, Cardinale D, Zorzino L et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin. Chem. 49(2), 248-252 (2003).
46. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109(22), 2749-2754 (2004).
47. Altinier S, Mion M, Cappelletti A et al. Rapid measurement of cardiac markers on Stratus CS. Clin. Chem. 46(7), 991-993 (2000).
48. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog. Cardiovasc. Dis. 53(2), 121-129 (2010).
49. Specchia G, Buquicchio C, Pansini N et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J. Lab. Clin. Med. 145(4), 212-220 (2005).
50. Kilickap S, Barista I, Akgul E et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann. Oncol. 16(5), 798-804 (2005).
51. Horacek JM, Pudil R, Jebavy L et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp. Oncol. 29(4), 309-313 (2007).
52. Horacek JM, Pudil R, Tichy M et al. Cardiac troponin I seems to be superior to cardiac troponin T in the early detection of cardiac injury associated with anthracycline treatment. Onkologie 31(10), 559-560 (2008).
53. Dodos F, Halbsguth T, Erdmann E et al. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin. Res. Cardiol. 97(5), 318-326 (2008).
54. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J. Clin. Oncol. 28(25), 3910-3916 (2010).
55. Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J. Clin. Oncol. 28(25), 3901-3904 (2010).
56. Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26(32), 5204-5212 (2008).
57. Morris PG, Chen C, Steingart R et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumaband lapatinib. Clin. Cancer Res. 17(10), 3490-3499 (2011).
58. Sawaya H, Sebag IA, Plana JC et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am. J. Cardiol. 107(9), 1375-1380 (2011).
59. Adamcová M, Simunek T, Kaiserová H et al. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug induced cardiotoxicity. Toxicology 237(1-3), 218-228 (2007).
60. Auner HW, Tinchon C, Linkesch W et al. Prolonged monitoring oftroponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann. Hematol. 82(4), 218-222 (2003).
61. Dolci A, Dominici R, Cardinale D et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am. J. Clin. Pathol. 130(5), 688-695 (2008).
62. Suzuki T, Hayashi D, Yamazaki T et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J. 136(2), 362-363 (1998).
63. Nousiainen T, Jantunen E, Vanninen E et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur. J. Haematol. 61(5), 347-353 (1998).
64. Hayakawa H, Komada Y, Hirayama M et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med. Pediatr. Oncol. 37(1), 4-9 (2001).
65. Meinardi MT, van Veldhuisen DJ, Gietema JA et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol. 19(10), 2746-2753 (2001).
66. Nousiainen T, Vanninen E, Jantunen E et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J. Intern. Med. 251(3), 228-234 (2002).
67. Daugaard G, Lassen U, Bie P et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur. J. Heart Fail. 7(1), 87-93 (2005).
68. Sandri MT, Salvatici M, Cardinale D et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin. Chem. 51(11), 1405-1410 (2005).
69. Pinarli FG, Ouz A, Tunaolu FS. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr. Blood Cancer 44(4), 370-377 (2005).
70. Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104(11), 2492-2498 (2005).
71. Pichon MF, Cvitkovic F, Hacene K et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 19(3), 567-576 (2005).
72. Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med. J. 26(8), 1197-1202 (2005).
73. Erkus B, Demirtas S, Yarpuzlu AA et al. Early prediction of anthracycline induced cardiotoxicity. Acta Pedriatr. 96(4), 506-509 (2007).
74. Aggarwal S, Pettersen MD, Bhambhani K et al. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr. Blood Cancer 49(6), 812-816 (2007).
75. Ekstein S, Nir A, Rein AJ et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J. Pediatr. Hematol. Oncol. 29(7), 440-444 (2007).
76. Zver S, Zadnik V, Bunc M et al. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int. J. Hematol. 85(5), 408-414 (2008).
77. Knobloch K, Tepe J, Lichtinghagen R et al. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. Int. J. Cardiol. 125(1), 113-115 (2008).
78. Broeyer FJ, Osanto S, Ritsema van Eck HJ et al. Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. J. Cancer Res. Clin. Oncol. 134(9), 961-968 (2008).
79. Mavinkurve-Groothuis AM, Groot-Loonen J, Bellersen L et al. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr. Blood Cancer 52(5), 631-636 (2009).
80. Cil T, Kaplan AM, Altintas A et al. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin. Drug Investig. 29(2), 131-137 (2009).
81. Roziakova L, Bojtarova E, Mistrik M et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J. Exp. Clin. Cancer Res. 31, 13 (2012).
82. Romano S, Fratini S, Ricevuto E et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br. J. Cancer 105(11), 1663-1668 (2011).
83. Lee HS, Son CB, Shin SH et al. Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity. Cancer Res. Treat. 40(3), 121-126 (2008).
84. Feola M, Garrone O, Occelli M et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int. J. Cardiol. 148(2), 194-198 (2011).
85. El Ghandour AH, El Sorady M, Azab S et al. Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. Hematol. Rev. 1(1), e6 (2009).
86. Horacek JM, Tichy M, Pudil R et al. Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity. Ann. Oncol. 19(9), 1656-1657 (2008).
87. Mercuro G, Cadeddu C, Piras A et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 12(9), 1124-1133 (2007).
88. Cadeddu C, Piras A, Mantovani G et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am. Heart J. 160(3), 487. e1-e7 (2010).
89. Nuver J, Smit AJ, Sleijfer DT et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur. J. Cancer 40(5), 701-706 (2004).
90. Vaughn DJ, Palmer SC, Carver JA et al. Cardiovascular risk in longterm survivors of testicular cancer. Cancer 112(9), 1949-1953 (2008).
91. Altena R, Perik P, van Veldhuisen DJ et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 10(4), 391-399 (2009).
92. Bonow RO, Bennett S, Casey DE Jr et al. American College of Cardiology; American Heart Association task force on performance measures; Heart Failure Society of America: ACC/AHA clinical performance measures for adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association task force on performance measures (Writing committee to develop heart failure clinical performance measures): endorsed by the Heart Failure Society of America. Circulation 112(12), 1853-1887 (2005).
93. Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist 13(12), 1224-1234 (2008).
94. Albini A, Pennesi G, Donatelli F et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J. Natl Cancer Inst. 102(1), 14-25 (2010).
95. Spallarossa P, Garibaldi S, Altieri P et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J. Mol. Cell. Cardiol. 37(4), 837-846 (2004).
96. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. 48(11), 2258-2262 (2006).
97. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23), 2474-2481 (2006).
98. Ederhy S, Massard C, Dufaitre G et al. Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in Phase 1 trials. Invest. N. Drugs 30(2), 611-615 (2010).
99. Felker GM, Thompson RE, Hare JM et al. Underlying causes and long-term survival in patientswith initially unexplained cardiomyopathy. N. Engl. J. Med. 342(15), 1077-1084 (2000).
100. Cardinale D, Colombo A, Cipolla CM. Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. Curr. Treat. Options Cardiovasc. Med. 10(6), 486-495 (2008).
101. Hunt SA, Abraham WT, Chin MH et al. ; American College of Cardiology Foundation; American Heart Association. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53(15), e1-e90 (2009
102. Yoon GJ, Telli ML, Kao DP et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies. Are clinicians responding optimally? J. Am. Coll. Cardiol. 56(20), 1644-1650 (2010).
103. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 55(3), 213-220 (2010).
104. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23(31), 7820-7826 (2005).
105. Telli ML, Hunt SA, Carlson RW et al. Trastuzumab related cardiotoxicity: calling into question the concept of reversibility. J. Clin. Oncol. 25(23), 3525-3533 (2007).